Masimo Co. (NASDAQ:MASI) Shares Acquired by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC grew its holdings in Masimo Co. (NASDAQ:MASI) by 2.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,778 shares of the medical equipment provider’s stock after purchasing an additional 97 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Masimo were worth $790,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in Masimo by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider’s stock valued at $758,182,000 after buying an additional 66,215 shares during the period. State Street Corp boosted its holdings in Masimo by 0.7% in the third quarter. State Street Corp now owns 1,438,814 shares of the medical equipment provider’s stock valued at $191,837,000 after purchasing an additional 10,179 shares during the period. Geode Capital Management LLC grew its stake in Masimo by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 792,886 shares of the medical equipment provider’s stock worth $105,741,000 after purchasing an additional 11,984 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Masimo by 2.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 377,836 shares of the medical equipment provider’s stock worth $62,456,000 after purchasing an additional 7,808 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. raised its position in Masimo by 0.4% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 373,705 shares of the medical equipment provider’s stock valued at $61,773,000 after purchasing an additional 1,522 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Insider Buying and Selling

In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of the company’s stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the sale, the director now directly owns 16,581 shares of the company’s stock, valued at $2,754,601.53. This represents a 11.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Bilal Muhsin sold 30,000 shares of Masimo stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the transaction, the chief operating officer now owns 24,172 shares in the company, valued at $4,048,568.28. This trade represents a 55.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is owned by company insiders.

Masimo Stock Performance

NASDAQ MASI opened at $144.40 on Monday. The company has a fifty day moving average of $173.64 and a two-hundred day moving average of $163.36. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. Masimo Co. has a 1 year low of $101.61 and a 1 year high of $194.88. The company has a market capitalization of $7.80 billion, a PE ratio of 99.59 and a beta of 1.28.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping the consensus estimate of $1.42 by $0.38. The company had revenue of $600.70 million for the quarter, compared to analyst estimates of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. As a group, analysts expect that Masimo Co. will post 4.1 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on MASI. Piper Sandler boosted their price objective on Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Raymond James increased their price objective on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research report on Friday, December 27th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research report on Wednesday, February 26th. Finally, Wells Fargo & Company increased their target price on Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Masimo has an average rating of “Moderate Buy” and a consensus target price of $194.80.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.